Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | XDH | P47989 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562980 | 0.82 | XDH (0.67) | KDM4ELMNASMN1; SMN2ALDH1A1XDH | |
| SCHEMBL22761420 | 0.79 | KDM4E (0.63) | KDM4ELMNASMN1; SMN2ALDH1A1XDH | |
| SCHEMBL1713191 | 0.76 | XDH (0.49) | LMNASMN1; SMN2XDH | |
| SCHEMBL21530644 | 0.74 | TSHR (0.46) | KDM4ELMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1713207 | 0.74 | CYP1A2 (0.43) | LMNASMN1; SMN2XDHHSD17B10 | |
| SCHEMBL11502949 | 0.73 | LMNA (0.44) | KDM4ELMNASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1186099 | 0.73 | KDM4E (0.68) | KDM4ELMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9669758 | 0.73 | XDH (0.50) | LMNASMN1; SMN2XDHTSHR | |
| SCHEMBL31590423 | 0.71 | KDM4E (0.66) | KDM4ELMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1417913 | 0.71 | KDM4E (0.81) | KDM4ELMNASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| WO-2008130313-A1 | IMIDAZOLE DERIVATIVES AS MODULATORS OF THE GABA RECEPTOR FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| EP-1761531-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001750-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | GABRB2, GABRA2, GABBR2 | KDM4E 2374/4885LMNA 4354/4885SMN1; SMN2 919/4885 |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | KDM4E 2917/4885LMNA 4323/4885SMN1; SMN2 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.